We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Julie Brahmer, MD, director of thoracic oncology and ...
The FDA has granted accelerated approval to zongertinib (Hernexeos; Boehringer Ingelheim Pharmaceuticals, Inc.) for adults with unresectable or metastatic non-squamous non–small cell lung cancer ...
Giredestrant Giredestrant (GIRE), an oral selective oestrogen receptor (ER) antagonist and degrader, + everolimus (E) in patients (pts) with ER-positive, HER2-negative advanced breast cancer (ER+, ...
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (ORIC), a clinical stage oncology company focused on developing treatments that address ...
The FDA granted zongertinib Breakthrough Therapy Designation for patients with HER2 (ERBB2)-mutant advanced NSCLC as an initial treatment. The FDA also awarded a Commissioner's National Priority ...
The approval was based on a cohort of treatment-naïve patients in the Beamion LUNG-1 trial who had unresectable or metastatic, non-squamous NSCLC with HER2 tyrosine kinase domain mutations.
In conjunction with the ESMO Asia Congress, ORIC will host a conference call and webcast on Saturday, December 6, 2025, at 8:00 pm ET. To join the conference call via phone and participate in the live ...
If you or a loved one has lung cancer, you may be looking into treatment options. A new medicine you might hear about is Hernexeos (zongertinib). More specifically, Hernexeos is FDA-approved to treat ...
Eyes will be on Eikon’s upcoming data readout for its toll-like receptors 7 and 8 (TLR7/8) co-agonist, as the company looks to buck the trend of recent clinical trial failures with candidates that ...
Lunit’s SCOPE IO artificial intelligence (AI)-based pathology platform has demonstrated its ability to generate biomarkers that predict patients’ response to immunotherapy across cancer types. Data ...
HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...
This press release is not intended for UK mediaHERNEXEOS® (zongertinib tablets) approved based on an objective response rate of 76% (N=72) as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results